BIIB News 334.39 08/01/2014 04:43:43 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 334.39 $BIIB

Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy

Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions

Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.

Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.

Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate

Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - Wed Jul 30, 4:30AM CDT
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.

Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.59%
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biogen Idec Rises 1.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).

Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.

Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).

Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid

Chipotle, Facebook Rally On Upside Earnings Surprise
at Investor's Business Daily - Fri Jul 25, 5:36PM CDT
Several leading stocks enjoyed solid, earnings-powered breakouts last week. The IBD 50 outperformed the overall market with a 3.2% gain, thanks to some outsized performances by some big names. Chipotle Mexican Grill (CMG) gapped up and soared 12%...

Celgene Beats Q2 Earnings Estimates on Strong Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 2:45PM CDT
Celgene (CELG) reported higher than expected earnings on strong revenues.

AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 10:52AM CDT
AbbVie (ABBV) will provide additional details on the upcoming Shire acquisition this fall.

Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 8:39AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 11% on the day.

Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:51AM CDT
Celsion Corp. (CLSN) was a big mover last session, as its shares rose over 5% on the day.

Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:44AM CDT
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares shoot up over 11% on the day.

Nasdaq stocks posting largest percentage increases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 19

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 88

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 150

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 81

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Changes in Leadership Position at ibex Limited

Updated Category News Views 289

Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...

Continue Reading
Umicore's Shareholding Update: Impact and Insights

Updated Category News Views 148

Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...

Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025

Updated Category News Views 212

Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...

Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation

Updated Category News Views 362

Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...

Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO

Updated Category News Views 289

Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...

Continue Reading